OM DENNE EPISODE
The CDER NextGen Portal (or the “Portal” for short) has made it easier than ever for regulated industry to communicate with the FDA.
Engelsk
USA
UDSKRIFT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SØG BLANDT TIDLIGERE EPISODER
Søg efter gamle afsnit af FDA CDER Small Business and Industry Assistance (SBIA) Chronicles.
ANDRE EPISODE I DENNE PODCAST
The Role of Pharmacodynamic Biomarkers in Biosimilar Drug Development
The FDA Compounding Incidents Program: Adverse Events Associated with Compounded Drugs from Outsourcing Facilities
FDA Regulation and Quality Considerations for Cannabis and Cannabis-Derived Compounds
Continuous manufacturing (CM) technology has the potential to improve product quality and reliability, lower manufacturing costs, reduce waste, decrease inventory, and increase manufacturing flexibility and agility in response to product demand.
Ansvarsfraskrivelse: Podcasten og kunstværket, der er indlejret på denne side, er fra U.S. Food and Drug Administration, Center for Drug Evaluation and Research, som tilhører dens ejer og ikke er tilknyttet eller godkendt af Listen Notes, Inc.
REDIG
Tak fordi du hjælper med at holde podcast-databasen opdateret.
